医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Digital Therapeutics Startup S-Alpha Therapeutics Raises $2.7M in Seed Funding

2020年12月17日 AM02:00
このエントリーをはてなブックマークに追加


 

SEOUL

On November 20th, S-Alpha Therapeutics (“S-Alpha” Seung Eun Choi, CEO), a digital therapeutics startup, completed a $2.7 Million USD (3 Billion KRW) seed round of funding from Hana Ventures, STIC Ventures, AJU IB Investment, SJ Investment Partners, and TONY Investment. This seed round follows an initial strategic investment from LegoChem Biosciences in February 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201216005185/en/

S-Alpha Therapeutics completed a $2.7 Million USD (3 Billion KRW) seed round of funding from Hana Ventures, STIC Ventures, AJU IB Investment, SJ Investment Partners, and TONY Investment. (Photo: Business Wire)

S-Alpha Therapeutics completed a $2.7 Million USD (3 Billion KRW) seed round of funding from Hana Ventures, STIC Ventures, AJU IB Investment, SJ Investment Partners, and TONY Investment. (Photo: Business Wire)

Hana Ventures led the seed round funding with the expectation of high growth in the digital therapeutics market. The company intends to use funds to execute clinical trials in the US to study their development stage digital therapeutic application intended to treat eye disease.

Dr. Myung Joon Kim, Chief Medical Officer at S-Alpha, leading the team to secure proprietary technologies for the discovery and development of the pipeline and internalization of the technology, commented, “The fact that S-Alpha consists of specialists from various areas including domestic and international clinical experts, biochemistry experts, and software application development experts, collaborating to develop digital therapeutics was highly valued by the investors. S-Alpha will continue its effort to develop cutting-edge digital therapeutics in several disease areas”.

About S-Alpha Therapeutics, Inc.

S-Alpha Therapeutics Inc., established in July 2019, is a digital therapeutics company with platform technologies that enable digital devices to treat different diseases. S-Alpha has a pipeline of products in the areas of ophthalmology, neuropsychiatry, cancer, and immunology.

S-Alpha’s lead product, SAT-001, is currently in the process of regulatory submission to start clinical studies in Korea as a therapeutic device for treating eye disease following MFDS’s guidance in June 2020. S-Alpha also completed a successful meeting in July 2020 with the USFDA on developing SAT-001 and is preparing to launch clinical studies in the United States. S-Alpha has an extensive product pipeline and collaborates actively with academic and industry partners to develop their R&D programs.

S-Alpha actively engages with the global digital therapeutics community and presented at the Digital Therapeutics East Conference (DTx East 2020) in September 2020 as the first Korean company to be invited to the conference.

S-Alpha is also a member of DTA (DTx Alliance), a non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics.

www.salphadtx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005185/en/

CONTACT

For media contact: Sanghun Lee

email: sanghun@salphadtx.com

Phone : 82-2-3487-3923

For Billing assistance: Aeran Jang (Admin Manager)

Email: aeran@salphadtx.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Regenacy Announces the Formation of a Joint Venture with 3E Bioventures to Develop Ricolinostat in China and the Start of a U.S. Phase 2 Study in Painful Diabetic Peripheral Neuropathy
  • Legend Biotech Announces Initiation of Rolling Submission of Biologics License Application to U.S. FDA Seeking Approval of BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
  • TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer
  • Shenpu Technology (KIEYYUEL) Made a Stunning Appearance at the International Epidemic Prevention Exhibition
  • Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD